Springer Nature

Springer Nature

By Springer NatureScience
Download on the App Store

Springer Nature episodes

  • Genomic responses to past and future change
    The genomes of organisms can tell us about evolutionary processes in the past - but can they also give clues about the future? André Yves and Fernanda Werneck tell us about their work on climate adaptation in Amazonian lizards.
    20 min
  • July 2025: ECI Katie Strobel
    Listen to July's Pediapod episode with ECI Katie Strobel, discussing her recent paper looking into the effect of early antibiotic exposure on necrotizing enterocolitis and growth in extremely preterm infants.
    14 min
  • Colourful signals in Anolis lizards
    Many Anolis lizards have a sail of colourful skin on their throats which they use to communicate, but how does something like that evolve? Find out with researchers Renata Pirani, Carlos Arias and Mike Logan.
    24 min
  • Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls
    There’s been a fair amount of animal data suggesting that nicotine can affect the developing brain, but there hadn’t been the equivalent human studies done on people whose brains are still developing. And today there are two predominant forms of nicotine delivery - tobacco cigarettes, and e-cigarettes, or vaping.
    Laurie Zawertailo is a senior scientist at the Center for Addiction and Mental Health in Toronto and an associate professor in the department of pharmacology and toxicology at the University of Toronto. Kanwar Boparai recently completed her PhD, working with Dr. Zawertailo, and is now a postdoc. For their new study, they and some colleagues recruited young adults age 18-25, and these people fell into three groups: one that had only smoked cigarettes, one that had only ever vaped, and a third that functioned as a control, that had never used either. They ended up with 26 smokers, 27 vapers, and 25 controls. This is the first human study to separate cigarette smokers and vapers into distinct groups.
    Read the full study here: https://www.nature.com/articles/s41386-025-02086-3
    9 min
  • Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
    Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.
    10 min

About Springer Nature

From the publisher's feed

Welcome to the Springer Nature Soundcloud page! Here you will find several podcasts from our journals across a range of scientific subjects, including Gene Pod, ModPath Chat, Pediapod, Hereditypod and…